Avid Bioservices Inc (CDMO)

[Big On Tarvy]

In 6 months we’ll have proof of our assets.

Today all we have is the start of critical clinical trials and a cash shortfall of $10-15 million if we do regional funding deals in India, and a $30 million shortfall if we don’t do regional funding deals.

Unfortunately, we need to turn one more funding corner and wait six months before we’ll have the clinical proof needed to dictate our price in BP licensing negotiations.

You and I may agree we are sitting on several blockbuster drugs, but BP is going to need to see the next round of clinical data before they pay the $500-900 M upfront price you suggest.